Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein L27 (RPL27) is a structural protein of the 60S ribosomal subunit, encoded by the RPL27 gene. It plays a key role in ribosome assembly, rRNA processing, and protein synthesis, with critical functions in cell proliferation and survival. Beyond its canonical role, RPL27 is implicated in human disease: mutations lead to Diamond-Blackfan anemia, while overexpression supports proliferation and stemness of cancer cells in colorectal and liver cancer. While not currently targeted by approved drugs, RPL27's essential role in translation and emerging data on its extra-ribosomal functions make it a candidate for future therapeutic targeting in cancer and hematologic disorders
Experimental: - Downregulation or knockdown suppresses cell proliferation and induces apoptosis in cancer models (mechanisms involve downregulation of cell cycle proteins like PLK1 and increased pro-apoptotic markers like Bax and Caspase-3, decreased Bcl-2). - Therapeutic targeting would likely aim to inhibit its function to suppress cancer cell viability and stemness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large ribosomal subunit protein L27 (RPL27).